A carregar...
Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model
BACKGROUND: Recent clinical studies have revealed that sodium glucose co-transporter 2 inhibitors (SGLT2i) reduced cardiovascular events in type 2 diabetes. Here, we investigated whether empagliflozin, as a kind of SGLT2i, could alleviate atherosclerosis progression in non-diabetic mice. METHODS: Ap...
Na minha lista:
| Publicado no: | J Inflamm Res |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8180283/ https://ncbi.nlm.nih.gov/pubmed/34103961 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JIR.S309427 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|